ANX-005 is a Monoclonal Antibody owned by Annexon, and is involved in 9 clinical trials, of which 3 were completed, 5 are ongoing, and 1 is planned.
ANX-005 inhibits early components of the classical complement cascade. C1q, the initiating protein of the classical cascade, regulates the elimination of nerve connections. In a number of neurological disorders, C1q interacts with nerve components to activate the classical complement cascade which causes significant damage to nerves and nerve connection.
The revenue for ANX-005 is expected to reach a total of $846m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ANX-005 NPV Report.
ANX-005 is under development for the treatment and acute antibody-mediated autoimmune disease such as Guillain-Barre syndrome, amyotrophic lateral sclerosis, warm autoimmune hemolytic anemia, Huntington disease and multifocal motor neuropathy (MMN). It is administered as intravenous infusion. The drug candidate is a humanized monoclonal antibody that inhibits early components of the classical complement cascade. It is based on composite human antibody technology. The drug candidate was also under development for the treatment of Alzheimer's disease.
Annexon is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates include ANX005 and ANX007, which are potent inhibitory antibodies against C1q, an initiating molecule of the classical complement cascade. The compay also develops ANX105, for the treatment of neurodegenerative disorders. It develops therapeutic products to protect against synapse loss and inflammatory nerve damage in brain and retinal cells. Annexon is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$130.7 million in FY2021, compared to an operating loss of US$63.5 million in FY2020. The net loss of the company was US$130.3 million in FY2021, compared to a net loss of US$63.4 million in FY2020.
Quick View – ANX-005
|Highest Development Stage|